OneDrug

New Study Confirms DPYD Genotype-Based Dosing Reduces Fluoropyrimidine Toxicity Risk 💊🧬

Genotype-guided dosing helps variant carriers match wild-type patients in safety—supporting updated guidelines!

BPS Publications Aims Several international guidelines recommend DPYD genotype-based dosing in patients treated with fluoropyrimidines. This study evaluates the incidences of severe fluoropyrimidine-related toxicity...

New Study Reveals Sub-Saharan CYP2D6 Variants May Alter Risperidone Metabolism, Highlighting Need for Ancestry-Informed Dosing

Cytochrome P450 2D6 *17 and *29 Allele Activity for Risperidone Metabolism: Advancing Precision Medicine Health Equity CYP2D6 alleles with low frequency in Eurocentrically biased study populations are often excluded from pharmacogenetic investigation and consequently may have misassigned activity values. This health ...

🔬🧠 Findings suggest certain PD gene polymorphisms predict remission, offering hope for personalized treatment approaches.

Association of pharmacodynamic genes with treatment outcomes in major depressive disorder: results from a Sardinian cohort - The Pharmacogenomics Journal We examined the association of selected candidate pharmacodynamic (PD) genes in MDD with treatment outcomes, defined according to remission thresholds for Hamilton Depression Rating Scale (HDRS) with 6- and 17- items. To this end, we recruited 158 individuals living with MDD followed in an academic....

Patient-Facing Pharmacogenetics Portal Boosts Understanding of Cancer Treatment Risks and Benefits

https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3747